Research map: Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study

Back to the article

Papers in this map

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  2. Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma · 2026 · Related
  3. CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas · Azael Freites‐Martínez · 2020 · 900 citations · Cited by this paper
  4. Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT · 2026 · Related
  5. Immunobiology and pathogenesis of hepatitis B virus infection · Matteo Iannacone · 2021 · 522 citations · Cited by this paper
  6. BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer · 2026 · Related
  7. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection · Markus Cornberg · 2025 · 420 citations · Cited by this paper
  8. Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients · 2026 · Related
  9. Single-cell spatial landscapes of the lung tumour immune microenvironment · Mark Sorin · 2023 · 406 citations · Cited by this paper
  10. Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives · 2026 · Related
  11. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC · Michael J. Grant · 2021 · 272 citations · Cited by this paper
  12. Time-dependent bias in local consolidative therapy for EGFR-mutant metastatic non-small cell lung cancer · 2026 · Related
  13. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 · Erin E. Conners · 2023 · 268 citations · Cited by this paper
  14. Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy · 2026 · Related
  15. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis · Urania G. Dafni · 2019 · 229 citations · Cited by this paper
  16. CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer · 2026 · Related
  17. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update · Jessica Park Hwang · 2020 · 214 citations · Cited by this paper
  18. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy · George K.K. Lau · 2021 · 185 citations · Cited by this paper
  19. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study · Shigeru Kusumoto · 2015 · 153 citations · Cited by this paper
  20. AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals · Faisal S. Ali · 2025 · 104 citations · Cited by this paper
  21. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer · Dan Pu · 2020 · 86 citations · Cited by this paper
  22. Checkpoint inhibitor hepatotoxicity: pathogenesis and management · Morven E. Cunningham · 2023 · 71 citations · Cited by this paper
  23. High titers of anti‐HBs prevent rituximab‐related viral reactivation in resolved hepatitis B patient with non‐Hodgkin's lymphoma · Yuri Cho · 2015 · 68 citations · Cited by this paper
  24. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies · Khalis Mustafayev · 2022 · 56 citations · Cited by this paper
  25. PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence · Seonggyu Byeon · 2020 · 52 citations · Cited by this paper
  26. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection · Ana Pertejo-Fernández · 2020 · 47 citations · Cited by this paper
  27. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis · Zhengzheng Xia · 2023 · 33 citations · Cited by this paper
  28. Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy · Xuanye Zhang · 2021 · 29 citations · Cited by this paper
  29. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis · Zi‐Niu Ding · 2022 · 27 citations · Cited by this paper
  30. Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review · Jian Zhao · 2022 · 16 citations · Cited by this paper
  31. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors · Khalis Mustafayev · 2024 · 15 citations · Cited by this paper
  32. Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study · Angioletta Lasagna · 2023 · 14 citations · Cited by this paper
  33. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B · Joo-Hyun Hong · 2024 · 10 citations · Cited by this paper
  34. Risk of Reactivation of Occult Hepatitis B During Immunotherapy in Cancer Treatment: Myth, Reality or New Horizons? · Angioletta Lasagna · 2021 · 8 citations · Cited by this paper
  35. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors · Bansi Savaliya · 2024 · 5 citations · Cited by this paper
  36. Viral Infection and Lung Cancer Immunotherapy · Ewa Kalinka‐Warzocha · 2021 · 4 citations · Cited by this paper
  37. Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection · Zhiting Zhao · 2022 · 3 citations · Cited by this paper
  38. Untitled · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)